Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005, 149(1):43-50 | DOI: 10.5507/bp.2005.003

DUAL ROLE OF CATHEPSIN D: LIGAND AND PROTEASE

Martin Fuseka, Václav Větvičkab
a Institute of Organic Chemistry and Biochemistry, CAS, Prague, Czech Republic, and
b University of Louisville, Department of Pathology, Louisville, KY40292, USA,

Cathepsin D is peptidase belonging to the family of aspartic peptidases. Its mostly described function is intracellular catabolism in lysosomal compartments, other physiological effect include hormone and antigen processing. For almost two decades, there have been an increasing number of data describing additional roles imparted by cathepsin D and its pro-enzyme, resulting in cathepsin D being a specific biomarker of some diseases. These roles in pathological conditions, namely elevated levels in certain tumor tissues, seem to be connected to another, yet not fully understood functionality. However, despite numerous studies, the mechanisms of cathepsin D and its precursor's actions are still not completely understood. From results discussed in this article it might be concluded that cathepsin D in its zymogen status has additional function, which is rather dependent on a "ligand-like" function then on proteolytic activity.

Keywords: Cathepsin D, Procathepsin D, Cancer, Activation peptide, Mitogenic activity, Proliferation

Received: April 15, 2005; Accepted: June 20, 2005; Published: July 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Fusek, M., & Větvička, V. (2005). DUAL ROLE OF CATHEPSIN D: LIGAND AND PROTEASE. Biomedical papers149(1), 43-50. doi: 10.5507/bp.2005.003
Download citation

References

  1. Dean RT. (1975) Direct evidence of importance of lysosomes in degradation of intracellular proteins, Nature 257, 414-416. Go to original source... Go to PubMed...
  2. Conner GE. Cathepsin D. In : Barrett AJ, Rawlings ND, Woessner JF editors. Handbook of Proteolytic Enzymes, New York: Academic press 2002. 746-751.
  3. Schwann T. (1836) Über das wesen des Verdaungsprocesses. Arch. Anat. Phys. Wiss. Med. 90, 1976,
  4. Tang (1970) Gastricsin and pepsin Methods. Enzymol. 19, 406- 421. Go to original source...
  5. Tang J, Wolf S, Caputto R, Trucco R.E. (1959) Isolation and crystallization of gastricsin from human gastric juice. J. Biol. Chem. 234, 1174-1178. Go to original source...
  6. Nishimura H. Comparative endocrinology of renin and angiotensin. In: Alan J, Anderson RR, editors. The Renin Angiotensin System. New York, Plenum Publishing , 1980. p. 29-77. Go to original source...
  7. Jupp RA, Richards AD, Kay J, Dunn BM, Wyckoff J.B., Samloff IM, Yamamoto K. (1988) Identification of aspartic proteinases from human erythrocyte membranes and gastric mucosa (slow moving proteinase) as catalytically equivalent to cathepsin E. Biochem J. 254, 895-898. Go to original source... Go to PubMed...
  8. Hong L, Koelsch G, Lin XL, Wu SL, Terzyan S, Ghosh AK, Zhang XC, Tang J. (2000) Structure of the protease domain of memapsin 2 ( secretase) complexed with inhibitor. Science 290, 150-153. Go to original source... Go to PubMed...
  9. Fusek M, Vetvicka V. Cathepsin D. In : Fusek M, Vetvicka V. editors. Aspartic Proteinases: Physiology and Pathology. Boca Ratton: CRC Press, 1995. p. 143-184. Go to original source...
  10. Hackenthal E, Paul M, Ganten D, Taugner R. (1990) Morphology, physiology, and molecular biology of renin secretion. Physiol.Rev. 70, 1067-1116. Go to original source...
  11. Tang J, James MNG, Hsu I, Jenkins JA, Blundell TL. (1978) Structural evidence for gene duplication in the evolution of the acid proteases. Nature 271, 618-621. Go to original source... Go to PubMed...
  12. James MNG, Sielecki AR. (1986) Molecular structure of an aspartic proteinase zymogen, porcine pepsinogen, at 1.8 resolution. Nature 319, 33-38 Go to original source... Go to PubMed...
  13. Hartsuck JA, Koelsch G, Remington SJ. (1992) The high-resolution crystal structure of porcine pepsinogen. Proteins: Structure, Function, Genetics 13, 1-25. Go to original source... Go to PubMed...
  14. Andreeva NS, Zdanov AS, Gustchina AE, Fedorov AA. (1984) Structure of ethanol inhibited porcine pepsin at 2 resolution and binding of the methylester of phenylalanyl-diodotyrosine to the enzyme. J.Biol.Chem. 259, 11353-11365. Go to original source... Go to PubMed...
  15. Cooper JB, Khan G, Taylor G, Tickle IJ, Blundell TL. (1990) X-ray analyses of aspartic proteinases. II Three dimensional structure of the hexagonal crystal form of porcine pepsin at 2.3 resolution. J.Mol.Biol. 214, 199-222. Go to original source... Go to PubMed...
  16. Metcalf P, Fusek M. (1993) Two crystal structures for cathepsin D: The lysosomal targeting signal and active site. EMBO J. 12, 1293-1302. Go to original source... Go to PubMed...
  17. Baldwin ET, Bhat TN, Gulnik S, Hosur MV, Sowder RC, Cachau RE, Collins J, Silva AM, Erickson JW. (1993) Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc. Natl. Acad. Sci. USA 90, 6796-6800. Go to original source...
  18. Sielecki AR, Hayakawa K, Fujinaga M, Murphy MEP, Fraser M, Muir AK, Carllil CT, Lewicki JA, Baxter JD, James MNG. (1989) Structure of recombinant human rennin, a target for cardiovascularactive drugs, at 2.5 resolution. Science 243, 1346-1351. Go to original source... Go to PubMed...
  19. Rahuel J, Priestle JP, Grutter MG. (1991) The crystal structures of recombinant glycosylated human rennin alone and on complex with transition state analog inhibitor. J.Structural Biol. 107, 227-36. Go to original source... Go to PubMed...
  20. Kageyama T, Ichinose M, Miki K, Athauda SB, Tanji M, Takahashi K. (1989) Difference of activation processes and structure of activation peptides in human pepsinogens A and progastricsin. J.Biochem. 105, 15-22. Go to original source... Go to PubMed...
  21. Conner GE, Richo G. Isolation and characterization of a stable activation intermediate of the lysosomal aspartyl protease cathepsin D. (1992) Biochemistry 31, 1142-1147. Go to original source... Go to PubMed...
  22. Schechter I, Berger A. (1967) On the size of the active site in proteases. I. Papain. Biochem, Biophys, Res. Commun. 27, 157-162. Go to original source... Go to PubMed...
  23. Horishima H, Takita T, Aoyagi T, Takeuchi T, Umezawa H. (1970) The structure of pepstatine, J. Antibiot. 23, 263-271. Go to original source... Go to PubMed...
  24. Abdel-Meguid SS. (1993) Inhibition of aspartyl proteinases. Med. Res.Rev. 13, 731-778. Go to original source... Go to PubMed...
  25. Dahms NM, Lobel P, Kornfeld S. (1989) Mannose-6-phosphate receptors and lysosomal enzyme targeting. J.Biol.Chem. 264, 12115-12118. Go to original source... Go to PubMed...
  26. von Figura K, Hasilik A (1986) Lysosomal enzymes and their receptors. Annu. Rev. Biochem. 55, 167-193. Go to original source... Go to PubMed...
  27. Dittmer F, Ulbrich EJ, Hafner A, Schmahl W, Meister T, Pohlmann R, von Figura K. (1999) Alternative mechanisms for trafficking of lysosomal enzymes in mannose 6-phosphate receptor-deficient mice are cell type-specific. J Cell Sci 112, 1591-1597. Go to original source... Go to PubMed...
  28. Zhu Y, Conner GE. (1994) Intermolecular association of lysosomal protein precursors during biosynthesis. J. Biol. Chem. 269, 3846-3851. Go to original source...
  29. Gopalakrishnan MM, Grosch H-W, Locatelli-Hoops S, Werth N, Smolenová E, Nettersheim M, Sandhoff K, Hasilik A. (2004) Purified recombinant human prosaponin forms oligomers that bind procathepsin D and affect its autoactivation, Biochem J. 383, 507-15. Go to original source... Go to PubMed...
  30. Koelsch G, Mares M, Metcalf P, Fusek M. (1994) Multiple functions of pro-parts of aspartic proteinase zymogens. FEBS Lett. 343, 6-10. Go to original source... Go to PubMed...
  31. Fusek M, Baudys M, Metcalf P(1992) Purification and crystallization of human cathepsin D. J. Mol. Biol. 226, 555-557. Go to original source... Go to PubMed...
  32. Mohamadzadeh M, Mohamadzadeh H, Brammer M, Sestak K, Luftig RB. (2004) Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD). J. Immune Based Ther. Vaccines 2, 8-10. Go to original source... Go to PubMed...
  33. Vetvicka V, Vagner J, Baudys M, Tang J, Foundling SI, Fusek M. (1993) Human breast milk contains procathepsin D-detection by specific antibodies. Biochem. Mol. Biol. Int. 30, 921-928.
  34. Safting P, Hetman M, Schmahl W. (1995) Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14, 3599-3608. Go to original source... Go to PubMed...
  35. Bidere N, Lorenzo HK, Carmona S, Laforge M, Harper F, Dumont C, Senik A. (2003) Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem. 278, 31401-31411. Go to original source... Go to PubMed...
  36. Shibata M, Kanamori S, Isahara K, OhsawaY, Konishi A, Kametaka S, Watanabe T, Ebisu S, Ishido K, Kominami E, UchiyamaY. (1998) Participation of cathepsins B and D in apoptosis of PC12 cells following serum deprivation. Biochem. Biophys. Res. Comm. 51, 199-203. Go to original source... Go to PubMed...
  37. Takuma K, Kiriu M, Mori K, Lee E, Enomoto R, Baba A, Matsuda T. (2003) Roles of cathepsins in reperfusion-induced apoptosis in cultured astrocytes. Neurochem. Int., 42 153-9. Go to original source... Go to PubMed...
  38. Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. (1996) Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha. EMBO J., 15, 3861-70. Go to original source... Go to PubMed...
  39. McIntyre GF, Erickson AH. (1991) Procathepsins L and D are membrane-bound in acidic microsomal vesicles. J.Biol.Chem. 266, 15438-15445. Go to original source... Go to PubMed...
  40. Diment S, Leech MS, Stahl PD (1998) Cathepsin D is membraneassociated in macrophage endosomes J.Biol.Chem. 263, 6901- 6907. Go to original source...
  41. Rochefort H, Capony F, Garcia M, Cavailles V, Freiss G, Chambon M, Morisset M, Vignon F. (1987) Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J. Cell. Biochem. 35. 17-29. Go to original source... Go to PubMed...
  42. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey J, Roger P. (2000) Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin. Chim. Acta. 291, 157-170. Go to original source... Go to PubMed...
  43. Vetvicka V, Benes P, Fusek M. (2002) Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors. Cancer Gene Ther. 9, 854-863. Go to original source... Go to PubMed...
  44. Cavailles V, Augereau P, Rochefort H. (1993) Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells., Proc. Natl. Acad. Sci. U S A. 90, 203-7. Go to original source... Go to PubMed...
  45. Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H. (1986) Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52K protein. Endocrinology 118, 1537-1545 Go to original source... Go to PubMed...
  46. Vetvicka V, Vetvickova J, Fusek M (1994) Effect of human procathepsin D on proliferation of human cell lines. Cancer Lett. 79, 131-135. Go to original source... Go to PubMed...
  47. Rochefort H. (1992) Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol. 31, 125-130. Go to original source... Go to PubMed...
  48. Rochefort H. (1992) Cathepsin D in breast cancer: A tissue marker associated with metastasis. Eur. J. Cancer 28A, 1780-1783. Go to original source... Go to PubMed...
  49. Leto G, Gebbia N, Rausa L, Tumminello FM. (1992) Cathepsin D in the malignant progression of neoplastic diseases, Anticancer Res. 12, 235-240. Go to PubMed...
  50. Leto G, Tumminello FM, Crescimanno M, Flandina C, Gebbia N. (2004) Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin. Exp. Metastases 21, 91-106. Go to original source... Go to PubMed...
  51. Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort H. (1997) Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro- cathepsin D immunoassay. Cancer 79, 2132-2136. Go to original source... Go to PubMed...
  52. Ferrandina G, Scambia G, Bardelli F, Panici PB, Mancuso S, Messori A. (1997) Relationship between cathepsin-D content and disease free survival in node-negative breast cancer patients: A meta-analysis. Br. J. Cancer 76, 661-666. Go to original source... Go to PubMed...
  53. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG. (1999) Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br. J. Cancer 79, 300-307. Go to original source... Go to PubMed...
  54. Roger S, Day CA, Fox SB. (1993) Expression of cathepsin D and estrogen receptors in male breast carcinoma. Human Pathol. 24, 148-151. Go to original source... Go to PubMed...
  55. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA. (2001) Clinical relevance of biological factors in male breast cancer. Breast Cancer Res. Treat 68, 249-60. Go to original source... Go to PubMed...
  56. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, Liaudet-Coopman E. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21, 5951-5955. Go to original source... Go to PubMed...
  57. Vetvicka V, Vetvickova J, Hilgert I, Voburka Z, Fusek M. (1997) Analysis of the interaction of procathepsin D activation peptide with breast cancer cells. Int J Cancer. 73, 403-9. Go to original source... Go to PubMed...
  58. Vetvicka V, Vetvickova J, Benes P. (2004) Role of enzymatically inactive procathepsin D in lung cancer. Anticancer Res. 24, 2739- 2743.
  59. Fusek M, Vetvicka V. (1994) Mitogenic function of human procathepsin D-role of the activation peptide. Biochem J 303, 775- 780. Go to original source... Go to PubMed...
  60. Glondu M, Coopman P, Laurent-Matha V, Garcia M, Rochefort H, Liaudet-Coopman E (2001) A mutated cathepsin D devoid of its catalytic activity stimulates the growth of cancer cells. Oncogene 20, 6920-6929. Go to original source... Go to PubMed...
  61. Laurent-Matha V, Maruani-Herrman S, Prebois C, Beaujoin M, Glondu M, Noel A, Alvarez-Gonzales ML, Blacher S, Coopman P, Baghdiguian S, Gilles C, Lancarek J, Freiss G, Vignon F, Liaudet- Coopman E. (2005) Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J. Cell Biol. 168, 489-499. Go to original source... Go to PubMed...
  62. Vetvicka V, Vetvickova J, Fusek M. (1999) Anti-human procathepsin D activation peptide antibodies inhibit breast cancer development. Breast. Cancer. Res. Treat. 57, 261-269. Go to original source... Go to PubMed...